Venous Thromboembolism During Pregnancy

Am Fam Physician. 2008 Jun 15;77(12):1709-1716.

Venous thromboembolism is the leading cause of maternal death in the United States. Pregnancy is a risk factor for deep venous thrombosis, and risk is further increased with a personal or family history of thrombosis or thrombophilia. Screening for thrombophilia is not recommended for the general population; however, testing for inherited or acquired thrombophilic conditions is recommended when personal or family history suggests increased risk. Factor V Leiden and prothrombin G20210A mutation are the most common inherited thrombophilias, and antiphospholipid antibody syndrome is the most important acquired defect. Clinical symptoms of deep venous thrombosis may be subtle and difficult to distinguish from gestational edema. Venous compression (Doppler) ultrasonography is the diagnostic test of choice. Pulmonary embolism typically presents postpartum with dyspnea and tachypnea. Multidetector-row (spiral) computed tomography is the test of choice for pulmonary embolism. Warfarin is contraindicated during pregnancy, but is safe to use postpartum and is compatible with breastfeeding. Low-molecular-weight heparin has largely replaced unfractionated heparin for prophylaxis and treatment in pregnancy.

Venous thromboembolism (VTE), which encompasses deep venous thrombosis (DVT) and pulmonary embolism (PE), complicates 0.5 to 3.0 per 1,000 pregnancies,1 and is the leading cause of maternal mortality in the United States.2 A 2007 American College of Physicians and American Academy of Family Physicians practice guideline,1 based on a systematic review,3 found only 11 high quality studies relating to the management of VTE in pregnancy, and concluded that there is inadequate evidence for definitive recommendations.1

SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendation Evidence rating References Comments

Multidetector-row (spiral) CT is the imaging modality of choice to evaluate for PE in pregnancy because, in nonpregnant patients, the diagnostic accuracy is equivalent to pulmonary angiography, and radiation exposure to the fetus is less than with a V/Q scan.

C

Non-pregnancy: 19

Non-pregnancy: clinical guideline19

Pregnancy: 12, 24, 27

Pregnancy: clinical guideline,12 expert review,24 and prospective cohort study27

LMWHs are recommended for the treatment of acute DVT and PE in pregnancy because of equivalent or superior effectiveness and safety compared with unfractionated heparin.

B

35

Systematic review

LMWHs are the agents of choice for antenatal thromboprophylaxis.

A

35, 42

Systematic review35 and Cochrane review42


CT = computed tomography; DVT = deep venous thrombosis; LMWH = low-molecular-weight heparin; PE = pulmonary embolism; VCUS = venous compression ultrasonography; V/Q = ventilation perfusion.

A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, see http://www.aafp.org/afpsort.xml.

SORT: KEY RECOMMENDATIONS FOR PRACTICE

View Table

SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendation Evidence rating References Comments

Multidetector-row (spiral) CT is the imaging modality of choice to evaluate for PE in pregnancy because, in nonpregnant patients, the diagnostic accuracy is equivalent to pulmonary angiography, and radiation exposure to the fetus is less than with a V/Q scan.

C

Non-pregnancy: 19

Non-pregnancy: clinical guideline19

Pregnancy: 12, 24, 27

Pregnancy: clinical guideline,12 expert review,24 and prospective cohort study27

LMWHs are recommended for the treatment of acute DVT and PE in pregnancy because of equivalent or superior effectiveness and safety compared with unfractionated heparin.

B

35

Systematic review

LMWHs are the agents of choice for antenatal thromboprophylaxis.

A

35, 42

Systematic review35 and Cochrane review42


CT = computed tomography; DVT = deep venous thrombosis; LMWH = low-molecular-weight heparin; PE = pulmonary embolism; VCUS = venous compression ultrasonography; V/Q = ventilation perfusion.

A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, see http://www.aafp.org/afpsort.xml.

Risk Factors

Virchow's triad of hypercoagulation, vascular damage, and venous stasis all occur in pregnancy, resulting in a relative risk of 4.3 (95% confidence interval [CI], 3.5 to 5.2) for VTE in pregnant or postpartum women compared with nonpregnant women.4

VTE risk factors include age greater than 35 years, obesity (body mass index higher than 30 kg per2), grand multiparity, and a personal or family history of VTE or thrombophilia.5,6 Bed rest, immobility for four days or longer, hyperemesis, dehydration, medical problems (e.g., severe infection, congestive heart failure, nephrotic syndrome), preeclampsia, severe varicose veins, surgery, and trauma are also associated with an increased risk.6,7 Cesarean delivery significantly increases VTE risk compared with vaginal delivery (odds ratio [OR] = 13.3; 95% CI, 3.4 to 51.4).8

Thrombophilic Disorders

Approximately 50 percent of pregnant women with VTE have a thrombophilia, compared with 10 percent of the general population.5 Current evidence does not support universal thrombophilia screening.9 However, expert opinion suggests testing women with a personal or strong family history of thrombosis or thrombophilia.10 During pregnancy, results must be interpreted with caution, because protein S levels normally fall in the second trimester.11 Massive thrombus and nephrotic syndrome can decrease antithrombin levels, and liver disease decreases protein C and S levels.12

Thrombophilic disorders may be inherited or acquired.13,14 Factor V Leiden and prothrombin G20210A mutations are the most common.13 Antiphospholipid antibody syndrome, the most important acquired thrombophilia in pregnancy, is defined by the presence of antiphospholipid antibodies and one or more clinical manifestations, most commonly thrombosis or recurrent miscarriage.15 A positive test for lupus anticoagulant, or medium-to-high titers of anticardiolipin immunoglobulin G or M antibodies, provides adequate laboratory confirmation of antiphospholipid antibody syndrome if found twice at least six weeks apart.15

Thrombophilias are associated with pregnancy complications, including early and late pregnancy loss, intra-uterine growth restriction, and placental abruption.9

Signs and Symptoms

DEEP VENOUS THROMBOSIS

DVT occurs with equal frequency in each trimester and postpartum.16 During pregnancy, 78 to 90 percent of DVTs occur in the left leg5,7 and 72 percent in the ilio-femoral vein, where they are more likely to embolize.5 In nonpregnant patients, 55 percent are in the left leg and 9 percent in the iliofemoral vein.5

Diagnosing DVT is difficult during pregnancy. Clinical suspicion is confirmed in 10 percent of pregnant women, compared with 25 percent of nonpregnant patients.17 Typical symptoms are unilateral leg pain and swelling. Pain with foot dorsiflexion (Homans' sign) is neither sensitive nor specific for diagnosing DVT in patients who are not pregnant;18 however, data are lacking for this in patients who are pregnant.

PULMONARY EMBOLISM

PE occurs more commonly during the postpartum period than during pregnancy (relative risk = 15.0; 95% CI, 5.1 to 43.9),4 and 64 percent of postpartum VTEs occur after cesarean delivery. 7 Clinical presentation varies from mild dyspnea and tachypnea to dramatic cardiopulmonary collapse. Symptoms of dyspnea are nonspecific in pregnancy. Of clinically suspected PE, only 4 percent are confirmed in pregnant patients, versus 30 percent in nonpregnant patients.17

Diagnostic Testing

DEEP VENOUS THROMBOSIS

Figure 1 presents an approach to the diagnosis and treatment of DVT in pregnancy derived from studies of non-pregnant patients.19,20 In nonpregnant women, a negative (low) d-dimer test combined with a low clinical probability score has a negative predictive value higher than 99.5 percent when a highly sensitive assay (e.g., enzyme-linked immunosorbent assay, latex turbidimetric assay) is used.19,20 However, d-dimer values increase progressively throughout pregnancy, and the ranges for normal values by gestational week are not yet universally established.21,22 Although a low d-dimer may be helpful in ruling out DVT, a positive (high) d-dimer result will be common during pregnancy and always requires confirmatory testing.12,20

Diagnosis and Treatment of DVT in Pregnancy

Figure 1.

Algorithm for diagnosis and treatment of DVT in pregnancy. (DVT = deep venous thrombosis; VCUS = venous compression ultrasonography.)

Information from references 19 and 20.

View Large

Diagnosis and Treatment of DVT in Pregnancy


Figure 1.

Algorithm for diagnosis and treatment of DVT in pregnancy. (DVT = deep venous thrombosis; VCUS = venous compression ultrasonography.)

Information from references 19 and 20.

Diagnosis and Treatment of DVT in Pregnancy


Figure 1.

Algorithm for diagnosis and treatment of DVT in pregnancy. (DVT = deep venous thrombosis; VCUS = venous compression ultrasonography.)

Information from references 19 and 20.

Venous compression ultrasonography is the test of choice for diagnosing DVT because it is noninvasive, safe, and relatively inexpensive.12,20 In nonpregnant patients, it is 89 to 96 percent sensitive and 94 to 99 percent specific for symptomatic proximal lower extremity DVT.19 Sensitivity is lower in patients who are asymptomatic or have a calf DVT.19 In nonpregnant patients, computed tomography and magnetic resonance imaging have equivalent or better sensitivities and specificities than ultrasonography for DVT detection.23 Data are lacking for pregnant patients.

Venography still serves as the definitive test for diagnosing DVT19 and may be used in clinical situations where noninvasive tests are equivocal, empiric anticoagulation is relatively contraindicated, and clinical suspicion is high.24

PULMONARY EMBOLISM

Figure 2 outlines a diagnostic approach for suspected PE based on expert opinion derived from studies mostly involving nonpregnant patients.2427

Diagnosis of PE in Pregnancy

Figure 2.

Algorithm for the diagnosis of PE in pregnancy. (CT = computed tomography; MRI = magnetic resonance imaging; PE = pulmonary embolism; VCUS = venous compression ultrasonography; V/Q = ventilation-perfusion.)

Information from references 24 through 27.

View Large

Diagnosis of PE in Pregnancy


Figure 2.

Algorithm for the diagnosis of PE in pregnancy. (CT = computed tomography; MRI = magnetic resonance imaging; PE = pulmonary embolism; VCUS = venous compression ultrasonography; V/Q = ventilation-perfusion.)

Information from references 24 through 27.

Diagnosis of PE in Pregnancy


Figure 2.

Algorithm for the diagnosis of PE in pregnancy. (CT = computed tomography; MRI = magnetic resonance imaging; PE = pulmonary embolism; VCUS = venous compression ultrasonography; V/Q = ventilation-perfusion.)

Information from references 24 through 27.

With low or moderate clinical suspicion, a negative highly sensitive d-dimer test rules out PE.25,28 If d-dimer testing is positive, or if clinical suspicion is high, additional testing is needed. Some authorities recommend lower extremity venous compression ultrasonography as the next test because if DVT is present, anticoagulant treatment will be the same as for PE, and venous compression ultrasonography avoids fetal radiation exposure.12,28

When d-dimer testing and venous compression ultrasonography are inconclusive, multidetector-row (spiral) computed tomography has become the test of choice for diagnosing PE in pregnancy.12,24,26 Single-slice computed tomography is inadequate in diagnosing peripheral PE, but newer-generation spiral computed tomography, tested in nonpregnant patients, has shown positive and negative predictive values comparable with pulmonary angiography.27 Fetal exposure to radiation is lower with spiral computed tomography than with ventilation-perfusion (V/Q) scanning (less than 130 μGy and 370 μGy, respectively), and fetal exposure to spiral computed tomography nonionic contrast appears safe.29 Spiral computed tomography does expose the maternal breast to greater radiation, and V/Q scanning may be preferred in women with a family history of breast cancer.12 A cost-benefit analysis supports spiral computed tomography as the preferred test for diagnosing PE during pregnancy.30

V/Q scanning may be used if spiral computed tomography is unavailable. Based on data from nonpregnant patients, PE can be excluded with a normal or low probability V/Q scan if clinical suspicion is low to moderate.25 Likewise, PE can be diagnosed with a high probability scan if clinical suspicion is moderate to high.25 In a study of V/Q scanning in 120 pregnant women with suspected PE, 73.5 percent were normal and 1.8 percent were high probability, compared with 27 to 36 percent normal and 8 to 14 percent high probability scans in nonpregnant patients.31 When V/Q scanning is nondiagnostic, additional options include repeat leg compression ultra-sonography, repeat V/Q scanning, spiral computed tomography, magnetic resonance imaging, and pulmonary angiography. Arterial blood gas monitoring (with the patient sitting upright for greatest accuracy), chest radiography, and electrocardiography (looking for right ventricular hypertrophy) can be done in unstable and immobile patients and may help diagnose PE or suggest other conditions.

Treatment

The optimal treatment of VTE during pregnancy has not been studied via randomized controlled trials, and clinical recommendations are based on expert opinion.10,12,24,32

Stabilization is the first priority. Airway, breathing, and circulation should be addressed immediately and may require management in the intensive care unit. With life-threatening PE, thrombolytic therapy, percutaneous catheter thrombus fragmentation, or surgical embolectomy may be used, depending on local resources.33 Good evidence about the effectiveness and safety of thrombolytic therapy is lacking.34 Empiric anticoagulation may be started if clinical suspicion is high, then discontinued if VTE is excluded.12

ANTICOAGULATION IN PREGNANCY

Therapeutic anticoagulation is indicated when DVT or PE is diagnosed. Anticoagulation options include low-molecular-weight heparins (LMWHs), unfractionated heparin (UFH), and warfarin (Coumadin; postpartum only).

LMWHs are replacing UFH as the first-choice medications for VTE treatment and prophylaxis in pregnancy.12,24,35 In nonpregnant women, randomized trials have shown LMWHs to have equivalent or better effectiveness compared with UFH.1,3,36 In pregnancy, a systematic review concluded that LMWH is safe and effective and that there is no evidence to favor one LMWH over another.35 Excretion in breast milk is minimal.37 Compared with UFH, LMWHs have lower rates of adverse effects, including heparin-induced thrombocytopenia, symptomatic osteoporosis, bleeding, and allergic reactions.35

Warfarin should be avoided during pregnancy. It crosses the placenta and increases the risk of miscarriage, stillbirth, embryopathy (nasal hypoplasia or stippled epiphyses), central nervous system abnormalities, and maternal and fetal hemorrhage.32 Warfarin is compatible with breastfeeding.32

Data derived from nonpregnant populations suggest that therapeutic anticoagulation following a first episode of VTE should continue for at least six months from diagnosis.38 Current recommendations for the duration of treatment in pregnancy range from three to six months, including six weeks postpartum.10,12,32 Long-term (i.e., longer than 12 months) anticoagulation is indicated for women with VTE and antiphospholipid antibody syndrome, or two or more thrombophilias,39 and for women with any thrombophilia and recurrent thrombotic events.40

Table 1 lists a typical therapeutic LMWH dose.10,12,32,41 The optimal monitoring protocol with LMWH is controversial. It is not necessary to follow the activated partial thromboplastin time.10 Anti-Xa levels need only be obtained in patients who are at extremes of weight (< 121 lb [55 kg] or > 198 lb [90 kg]) or have abnormal renal function.12 Monitoring of platelets while on LMWH is no longer recommended.12 UFH may be used instead of LMWH for the treatment of VTE in pregnancy, because of cost or availability.

Table 1

Therapeutic Dosing of Heparin in Pregnancy

Drug Dosage*

LMWH (enoxaparin[Lovenox])

1 mg per kg subcutaneously every12 hours12

UFH

IV loading dose of 5,000 IU

followed by

Continuous IV infusion for a total of at least 30,000 IU over 24 hours10

or

10,000 IU subcutaneously every 8 hours41

or

20,000 IU subcutaneously every 12 hours41

Monitor aPTT and adjust dose to maintain aPTT 1.5 to 2 times control value32


aPTT = activated partial thromboplastin time; IV = intravenous; IU = International Units; LMWH = low-molecular-weight heparin; UFH = unfractionated heparin.

*— Subcutaneous LMWH or adjusted-dose subcutaneous UFH can be used for initial and long-term treatment. IV UFH is followed by subcutaneous LMWH or adjusted-dose subcutaneous UFH.32

Information from references 10, 12, 32, and 41.

Table 1   Therapeutic Dosing of Heparin in Pregnancy

View Table

Table 1

Therapeutic Dosing of Heparin in Pregnancy

Drug Dosage*

LMWH (enoxaparin[Lovenox])

1 mg per kg subcutaneously every12 hours12

UFH

IV loading dose of 5,000 IU

followed by

Continuous IV infusion for a total of at least 30,000 IU over 24 hours10

or

10,000 IU subcutaneously every 8 hours41

or

20,000 IU subcutaneously every 12 hours41

Monitor aPTT and adjust dose to maintain aPTT 1.5 to 2 times control value32


aPTT = activated partial thromboplastin time; IV = intravenous; IU = International Units; LMWH = low-molecular-weight heparin; UFH = unfractionated heparin.

*— Subcutaneous LMWH or adjusted-dose subcutaneous UFH can be used for initial and long-term treatment. IV UFH is followed by subcutaneous LMWH or adjusted-dose subcutaneous UFH.32

Information from references 10, 12, 32, and 41.

UFH is considered an acceptable alternative.32  Table 1 recommends dosages and monitoring.10,12,32,41 For postpartum DVT or PE, warfarin may be started concomitantly with heparin.42 LMWH or UFH should be continued until an international normalized ratio of 2.0 to 3.0 is achieved for two consecutive days.42 Post-thrombotic syndrome can be prevented if compression stockings are worn for at least one year starting in the first month after a DVT.1

DELIVERY IN PATIENTS TAKING ANTICOAGULANTS

Intrapartum management may vary depending on the indication for anticoagulation and whether therapeutic or prophylactic doses have been used.10 Expert guidelines suggest that women receiving adjusted-dose LMWH or UFH be instructed to discontinue heparin injections at the onset of labor to prevent anticoagulant complications during delivery.12,32 When delivery is predictable, as for elective induction or planned cesarean birth, LMWH or UFH should be discontinued 24 hours before delivery.12,32 For high-risk patients, such as those with mechanical heart valves or recent VTE, the American College of Obstetricians and Gynecologists (ACOG) recommends switching to intravenous heparin at the onset of labor.10 The short half-life of intravenous UFH allows discontinuation four to six hours before the anticipated time of delivery.10,32 To minimize spinal and epidural hematoma risk, the ACOG and the American Society of Regional Anesthesia advise avoiding regional anesthesia for 24 hours after the last LMWH dose for women on twice daily therapeutic doses of enoxaparin (Lovenox), and for 12 hours after the last dose of LMWH for women receiving daily prophylactic dosing.10

WHEN ANTICOAGULATION IS CONTRAINDICATED OR INEFFECTIVE

Evidence is insufficient to recommend for or against an inferior vena cava filter if anticoagulation is contraindicated or repeat PE occurs despite adequate anticoagulation.1

Prophylaxis

Systematic reviews of observational studies have found VTE prophylaxis with LMWH to be safe and effective in pregnancy, but there are no randomized controlled trials confirming this.35,42  Table 2 lists representative prophylactic doses of LMWH and subcutaneous UFH.6,43  Table 3 summarizes recommendations for the type and duration of prophylaxis based on specific clinical risk factors.5,10,15,32,39,40 Consultation should be considered for high-risk thrombophilias such as antithrombin deficiency.6

Table 2

Prophylactic Dosing of Heparin in Pregnancy

Weight Dosage

Enoxaparin (Lovenox)6

110 to 199 lb (50 to 90 kg)

40 mg SC daily

< 110 lb

20 mg SC daily

> 199 lb

40 mg SC every 12 hours

UFH43

First trimester

5,000 IU SC twice daily

Second trimester

7,500 IU SC twice daily

Third trimester

10,000 IU SC twice daily


IU = International Units; SC = subcutaneously; UFH = unfractionated heparin.

Information from references 6 and 43

Table 2   Prophylactic Dosing of Heparin in Pregnancy

View Table

Table 2

Prophylactic Dosing of Heparin in Pregnancy

Weight Dosage

Enoxaparin (Lovenox)6

110 to 199 lb (50 to 90 kg)

40 mg SC daily

< 110 lb

20 mg SC daily

> 199 lb

40 mg SC every 12 hours

UFH43

First trimester

5,000 IU SC twice daily

Second trimester

7,500 IU SC twice daily

Third trimester

10,000 IU SC twice daily


IU = International Units; SC = subcutaneously; UFH = unfractionated heparin.

Information from references 6 and 43

Table 3

Clinical Indications for Anticoagulant Prophylaxis

Personal history of DVT or PE, no known thrombophilia

DVT or PE with thrombogenic event (e.g., hip fracture, prolonged surgery)

Start: This indication is controversial; patient and caregivers may decide whether to use antenatal heparin prophylaxis; regardless of this decision, postpartum prophylaxis is recommended10,32

Stop: Six weeks postpartum10

DVT or PE with no thrombogenic event

Start: As early in pregnancy as possible10

Stop: Six weeks postpartum;10 those with recurrent or life-threatening events may require long-term prophylaxis40

Personal history of DVT or PE, known thrombophilia

Start: As early in pregnancy as possible10

Stop: Six weeks postpartum;10 12 months or longer of anticoagulation is indicated for nonpregnant patients with a first episode of VTE (DVT or PE) and antiphospholipid syndrome or combined factor V Leiden and prothrombin G20210A mutations;39 six to 12 months of anticoagulation is indicated for nonpregnant patients with a first episode of VTE and antithrombin, protein C or S deficiencies, heterozygous factor V Leiden or prothrombin G20210A mutations, homocystinemia or factor VIII levels > 90 percent of normal;39 lower-quality evidence suggests long-term anticoagulation for nonpregnant patients with a first episode of VTE and any of the above thrombophilias;39 women with any thrombophilia and recurrent or life-threatening events may require long-term prophylaxis40

No history of DVT or PE, known thrombophilia

Antithrombin deficiency, homozygous factor V Leiden; two or more minor risk factors (i.e., heterozygous factor V Leiden and heterozygous prothrombin G20210A mutations)

Start: As early in pregnancy as possible10

Stop: Six weeks postpartum10

Antiphospholipid antibodies

Start: Low-dose aspirin with or without heparin as early in pregnancy as possible15

Stop: Six to eight weeks postpartum15

Protein C or S deficiency

Start: As early in pregnancy as possible;5 peripartum and postpartum may be sufficient if no family history of thrombophilia, no severe protein C deficiency (less than 50 percent of normal levels), and no additional risk factor, such as immobilization, hospitalization, surgery, infection or thrombophlebitis5

Stop: Six weeks postpartum5

Single heterozygous factor V Leiden or heterozygous prothrombin G20210A mutation

Start: No prophylaxis indicated unless family history of venous thromboembolism and additional risk factor such as immobilization, hospitalization, surgery, infection, or thrombophlebitis;5 prophylaxis started peripartum or postpartum when indicated5

Stop: Four to six weeks postpartum5


DVT = deep venous thrombosis; PE = pulmonary embolism; VTE = venous thromboembolism.

Information from references 5, 10, 15, 32, 39, and 40.

Table 3   Clinical Indications for Anticoagulant Prophylaxis

View Table

Table 3

Clinical Indications for Anticoagulant Prophylaxis

Personal history of DVT or PE, no known thrombophilia

DVT or PE with thrombogenic event (e.g., hip fracture, prolonged surgery)

Start: This indication is controversial; patient and caregivers may decide whether to use antenatal heparin prophylaxis; regardless of this decision, postpartum prophylaxis is recommended10,32

Stop: Six weeks postpartum10

DVT or PE with no thrombogenic event

Start: As early in pregnancy as possible10

Stop: Six weeks postpartum;10 those with recurrent or life-threatening events may require long-term prophylaxis40

Personal history of DVT or PE, known thrombophilia

Start: As early in pregnancy as possible10

Stop: Six weeks postpartum;10 12 months or longer of anticoagulation is indicated for nonpregnant patients with a first episode of VTE (DVT or PE) and antiphospholipid syndrome or combined factor V Leiden and prothrombin G20210A mutations;39 six to 12 months of anticoagulation is indicated for nonpregnant patients with a first episode of VTE and antithrombin, protein C or S deficiencies, heterozygous factor V Leiden or prothrombin G20210A mutations, homocystinemia or factor VIII levels > 90 percent of normal;39 lower-quality evidence suggests long-term anticoagulation for nonpregnant patients with a first episode of VTE and any of the above thrombophilias;39 women with any thrombophilia and recurrent or life-threatening events may require long-term prophylaxis40

No history of DVT or PE, known thrombophilia

Antithrombin deficiency, homozygous factor V Leiden; two or more minor risk factors (i.e., heterozygous factor V Leiden and heterozygous prothrombin G20210A mutations)

Start: As early in pregnancy as possible10

Stop: Six weeks postpartum10

Antiphospholipid antibodies

Start: Low-dose aspirin with or without heparin as early in pregnancy as possible15

Stop: Six to eight weeks postpartum15

Protein C or S deficiency

Start: As early in pregnancy as possible;5 peripartum and postpartum may be sufficient if no family history of thrombophilia, no severe protein C deficiency (less than 50 percent of normal levels), and no additional risk factor, such as immobilization, hospitalization, surgery, infection or thrombophlebitis5

Stop: Six weeks postpartum5

Single heterozygous factor V Leiden or heterozygous prothrombin G20210A mutation

Start: No prophylaxis indicated unless family history of venous thromboembolism and additional risk factor such as immobilization, hospitalization, surgery, infection, or thrombophlebitis;5 prophylaxis started peripartum or postpartum when indicated5

Stop: Four to six weeks postpartum5


DVT = deep venous thrombosis; PE = pulmonary embolism; VTE = venous thromboembolism.

Information from references 5, 10, 15, 32, 39, and 40.

Low-dose aspirin (75 to 81 mg) is sometimes used for women with an increased risk of thrombosis that does not meet the threshold for prophylactic heparin (e.g., a woman with a mild thrombophilia and no history of VTE).6 Due to the lack of studies of aspirin for this indication, such treatment is of unknown benefit; however, low-dose aspirin is safe to use during pregnancy.32

Postpartum thromboprophylaxis is not routinely indicated following vaginal delivery,42 but may become necessary because of labor-related risk factors, such as prolonged labor, mid-forceps delivery, and immobility after delivery.6

Unless other VTE risk factors are also present, women who undergo a scheduled cesarean delivery are not routinely placed on pharmacologic VTE prophylaxis.44 However, mechanical prophylaxis with pneumatic compression stockings has been shown to provide effective post-cesarean thromboprophylaxis.45 Graduated compression stockings provide effective prophylaxis in nonpregnant postoperative patients.46 A decision analysis comparing pneumatic compression stockings with no intervention for post-cesarean VTE prophylaxis found the former to be cost-effective.47

The Authors

LEE T. DRESANG, MD, is an associate professor and departmental maternity care clinical coordinator in the Department of Family Medicine at the University of Wisconsin School of Medicine and Public Health, Madison. He is a graduate of Indiana University School of Medicine, Indianapolis, and completed a family practice residency at the University of New Mexico, Albuquerque, and the Tacoma Family Medicine Rural Health Fellowship in Tacoma, Washington. Dr. Dresang is a member of the Advanced Life Support in Obstetrics (ALSO) Advisory Board.

PAT FONTAINE, MD, MS, is an associate professor of family medicine and community health at the University of Minnesota, Minneapolis. She is a graduate of the University of Michigan Medical School, Ann Arbor, and completed a family medicine residency at the North Memorial Program of the University of Minnesota Affiliated Family Medicine Residencies.

LARRY LEEMAN, MD, MPH, is an associate professor of family and community medicine, and obstetrics and gynecology, at the University of New Mexico School of Medicine, Albuquerque. He is co-medical director of the mother-baby unit at the University of New Mexico Hospital, Albuquerque. Dr. Leeman is a graduate of the University of California, San Francisco, School of Medicine. He completed a family medicine residency at the University of New Mexico School of Medicine and a fellowship in obstetrics at the University of Rochester (N.Y.) School of Medicine.

VALERIE J. KING, MD, MPH, is an associate professor in the Department of Family Medicine at Oregon Health & Science University, Portland. She is an ALSO Advisory Faculty member. She completed medical school, residencies in family and preventive medicine, and research fellowships at the University of North Carolina at Chapel Hill.

Address correspondence to Lee T. Dresang, MD, University of Wisconsin School of Medicine and Public Health, Dept. of Family Medicine, 701 Dane St., Madison, WI 53713 (e-mail: Lee.Dresang@fammed.wisc.edu). Reprints are not available from the authors.

Author disclosure: Nothing to disclose.

REFERENCES

1. Snow V, Qaseem A, Barry P, et al., for the American College of Physicians, American Academy of Family Physicians Panel on Deep Venous Thrombosis/Pulmonary Embolism. Management of venous thrombo-embolism: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med. 2007;146(3):204–210.

2. Chang J, Elam-Evans LD, Berg CJ, et al. Pregnancy-related mortality surveillance—United States, 1991–1999. MMWR Surveill Summ. 2003;52(2):1–8.

3. Segal JB, Streiff MB, Hofmann LV, Thornton K, Bass EB. Management of venous thromboembolism: a systematic review for a practice guideline [published correction appears in Ann Intern Med. 2007;146(5):396]. Ann Intern Med. 2007;146(3):211–222.

4. Heit JA, Kobbervig CE, James AH, Petterson TM, Bailey KR, Melton LJ. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med. 2005;143(10):697–706.

5. Zotz RB, Gerhardt A, Scharf RE. Prediction, prevention and treatment of venous thromboembolic disease in pregnancy. Semin Thromb Hemost. 2003;29(2):143–154.

6. Nelson-Piercy C. Thromboprophylaxis during pregnancy, labour and after vaginal delivery. Royal College of Obstetricians and Gynaecologists, 2004. Guideline no. 37. http://www.rcog.org.uk/resources/Public/pdf/Thromboprophylaxis_no037.pdf. Accessed February 23, 2008.

7. Blanco-Molina A, Trujillo-Santos J, Criado J, et al., for the RIETE Investigators. Venous thromboembolism during pregnancy or postpartum: findings from the RIETE Registry. Thromb Haemost. 2007;97(2):186–190.

8. Deneux-Tharaux C, Carmona E, Bouvier-Colle MH, Breart G. Postpartum maternal mortality and cesarean delivery. Obstet Gynecol. 2006;108(3 pt 1):541–548.

9. Robertson L, Wu O, Langhorne P, et al., for the Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Thrombophilia in pregnancy: a systematic review. Br J Haematol. 2006;132(2):171–196.

10. American College of Obstetricians and Gynecologists. Thromboembolism in pregnancy. ACOG Practice Bulletin No. 19. Obstet Gynecol. 2000;96(2):1–10.

11. Faught W, Garner P, Jones G, Ivey B. Changes in protein C and protein S levels in normal pregnancy. Am J Obstet Gynecol. 1995;172(1 pt 1):147–150.

12. Greer IA, Thomson AJ. Thromboembolic disease in pregnancy and the puerperium: acute management. Guidelines and Audit Committee of the Royal College of Obstetricians and Gynaecologists, 2007. Guideline no. 28. http://www.rcog.org.uk/resources/Public/pdf/green_top_28_thromboembolic_minorrevision.pdf. Accessed February 23, 2008.

13. Gerhardt A, Scharf RE, Zotz RB. Effect of hemostatic risk factors on the individual probability of thrombosis during pregnancy and the puerperium. Thromb Haemost. 2003;90(1):77–85.

14. Friederich PW, Sanson BJ, Simioni P, et al. Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: implications for prophylaxis [published corrections appear in Ann Intern Med. 1997;127(12):1138, and Ann Intern Med. 1997;126(10):835]. Ann Intern Med. 1996;125(12):955–960.

15. American College of Obstetricians and Gynecologists. Antiphospholipid syndrome: ACOG Practice Bulletin No. 68. Obstet Gynecol. 2005;106(5 pt 1):1113–1121.

16. Gherman RB, Goodwin TM, Leung B, Byrne JD, Hethumumi R, Montoro M. Incidence, clinical characteristics, and timing of objectively diagnosed venous thromboembolism during pregnancy. Obstet Gynecol. 1999;94(5 pt 1):730–734.

17. Ginsberg JS, Greer I, Hirsh J. Use of antithrombotic agents during pregnancy. Chest. 2001;119(1 suppl):122S–131S.

18. Urbano FL. Homans' sign in the diagnosis of deep venous thrombosis. Hosp Physician. March 2001:22–24. http://www.jcomjournal.com/pdf/hp_mar01_homan.pdf. Accessed February 23, 2008.

19. Qaseem A, Snow V, Barry P, et al., for the Joint American Academy of Family Physicians/American College of Physicians Panel on Deep Venous Thrombosis/Pulmonary Embolism. Current diagnosis of venous thromboembolism in primary care: a clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians. Ann Intern Med. 2007;146(6):454–458.

20. Michiels JJ, Freyburger G, van der Graaf F, Janssen M, Oortwijn W, Van Beek E. Strategies for the safe and effective exclusion and diagnosis of deep vein thrombosis by the sequential use of clinical score, d-dimer testing, and compression ultrasonography. Semin Thromb Hemost. 2000;26(6):657–667.

21. Morse M. Establishing a normal range for d-dimer levels through pregnancy to aid in the diagnosis of pulmonary embolism and deep vein thrombosis. J Thromb Haemost. 2004;2(7):1202–1204.

22. Francalanci I, Comeglio P, Alessandrello Liotta A, et al. d-dimer plasma levels during normal pregnancy measured by specific ELISA. Int J Clin Lab Res. 1997;27(1):65–67.

23. Kanne JP, Lalani TA. Role of computed tomography and magnetic resonance imaging for deep venous thrombosis and pulmonary embolism. Circulation. 2004;109(12 suppl 1):115–121.

24. Krivak TC, Zorn KK. Venous thromboembolism in obstetrics and gynecology. Obstet Gynecol. 2007;109(3):761–777.

25. Roy PM, Colombet I, Durieux P, Chatellier G, Sors H, Meyer G. Systematic review and meta-analysis of strategies for the diagnosis of suspected pulmonary embolism. BMJ. 2005;331(7511):259.

26. Matthews S. Short communication: imaging pulmonary embolism in pregnancy: what is the most appropriate imaging protocol? Br J Radiol. 2006;79(941):441–444.

27. Quiroz R, Kucher N, Zou KH, et al. Clinical validity of a negative computed tomography scan in patients with suspected pulmonary embolism: a systematic review. JAMA. 2005;293(16):2012–2017.

28. Stein PD, Woodard PK, Weg JG, et al. Diagnostic pathways in acute pulmonary embolism: recommendations of the PIOPED II investigators. Am J Med. 2006;119(12):1001–1002.

29. Winer-Muram HT, Boone JM, Brown HL, Jennings SG, Mabie WC, Lombardo GT. Pulmonary embolism in pregnant patients: fetal radiation dose with helical CT. Radiology. 2002;224(2):487–492.

30. Doyle NM, Ramirez MM, Mastrobattista JM, Monga M, Wagner LK, Gardner MO. Diagnosis of pulmonary embolism: a cost-effectiveness analysis. Am J Obstet Gynecol. 2004;191(3):1019–1023.

31. Chan WS, Ray JG, Murray S, Coady GE, Coates G, Ginsberg JS. Suspected pulmonary embolism in pregnancy: clinical presentation, results of lung scanning, and subsequent maternal and pediatric outcomes. Arch Intern Med. 2002;162(10):1170–1175.

32. Bates SM, Greer IA, Hirsh J, Ginsberg JS. Use of antithrombotic agents during pregnancy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 suppl):627S–644S.

33. Pillny M, Sandmann W, Luther B, et al. Deep venous thrombosis during pregnancy and after delivery: indications for and results of thrombectomy. J Vasc Surg. 2003;37(3):528–532.

34. Dong B, Jirong Y, Liu G, Wang Q, Wu T. Thrombolytic therapy for pulmonary embolism. Cochrane Database Syst Rev. 2006;(2):CD004437.

35. Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thrombo-prophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood. 2005;106(2):401–407.

36. van Dongen CJ, van den Belt AA, Prins MH, Lensing AW. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev. 2004;(4):CD001100.

37. Richter C, Sitzmann J, Lang P, Weitzel H, Huch A, Huch R. Excretion of low molecular weight heparin in human milk. Br J Clin Pharmacol. 2001;52(6):708–710.

38. Schulman S, Rhedin AS, Lindmarker P, Carlsson A, Lärfars G, Nicol P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med. 1995;332(25):1661–1665.

39. Büller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Anti-thrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy [published correction appears in Chest. 2005;127(1):416]. Chest. 2004;126(3 suppl):401S–428S.

40. Schulman S, Granquist S, Holström M, et al. The duration of oral anticoagulant therapy after a second episode of thromboembolism. Duration of Anticoagulation Trial Study Group. N Engl J Med. 1997;336(6):393–398.

41. Ramin SM, Ramin KD, Gilstrap LC. Anticoagulants and thrombolytics during pregnancy. Semin Perinatol. 1997;21(2):149–153.

42. Gates S, Brocklehurst P, Davis LJ. Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period. Cochrane Database Syst Rev. 2002;(2):CD001689.

43. Kent N, Leduc L, Crane J, et al. Prevention and treatment of venous thromboembolism (VTE) in obstetrics. J SOGC. 2000;22(9):736–749.

44. Jacobsen AF, Drolsum A, Klow NE, Dahl GF, Qvigstad E, Sandset PM. Deep vein thrombosis after elective cesarean section. Thromb Res. 2004;113(5):283–288.

45. Quiñones JN, James DN, Stamilio DM, Cleary KL, Macones GA. Thromboprophylaxis after cesarean delivery: a decision analysis. Obstet Gynecol. 2005;106(4):733–740.

46. Amaragiri SV, Lees TA. Elastic compression stockings for prevention of deep vein thrombosis. Cochrane Database Syst Rev. 2000;(3):CD001484.

47. Casele H, Grobman WA. Cost-effectiveness of thromboprophylaxis with intermittent pneumatic compression at cesarean delivery. Obstet Gynecol. 2006;108(3 pt 1):535–540.

This article is one in a series on “Advanced Life Support in Obstetrics (ALSO),” initially established by Mark Deutchman, MD, Denver, Colo. The series is now coordinated by Patricia Fontaine, MD, MS, ALSO Managing Editor, Minneapolis, Minn., and Larry Leeman, MD, MPH, ALSO Associate Editor, Albuquerque, N.M.


Copyright © 2008 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Article Tools

  • Download PDF
  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

More in Pubmed

Navigate this Article